At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 742 enrolled
Drug / intervention
Tazarotene Foam +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris
In Brief
A Phase 3 clinical trial evaluating Tazarotene Foam and Vehicle Foam for Acne Vulgaris. Completed, enrolled 742 participants across 18 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesCanada, United States
CollaboratorsGlaxoSmithKline
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedNov 2009
Primary CompletionNov 2010
Study CompletionNov 2010
TodayJul 2026
First PostedNov 20, 2009
Enrollment StartOct 1, 2009
Primary CompletionNov 1, 2010
Study CompletionNov 9, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.6 years ago
Interventions
Tazarotene Foamdrug
Tazarotene foam once a day application to the face
Vehicle Foamdrug
Vehicle Foam once a day application to the face